Price (delayed)
$189.23
Market cap
$85.73B
P/E Ratio
37.03
Dividend/share
$1.67
EPS
$5.11
Enterprise value
$90.9B
Zoetis Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's
Highlights
ZTS's revenue is up by 8% YoY and by 2.1% QoQ
The gross profit has grown by 8% YoY
The P/E is 8% lower than the 5-year quarterly average of 40.4 but 5% higher than the last 4 quarters average of 35.2
Zoetis's quick ratio has decreased by 4.1% YoY and by 3.5% QoQ
Key stats
What are the main financial stats of ZTS
Market
Valuations
Earnings
Shares outstanding
453.05M
Market cap
$85.73B
Enterprise value
$90.9B
Price to earnings (P/E)
37.03
Price to book (P/B)
17.39
Price to sales (P/S)
9.67
EV/EBIT
29.03
EV/EBITDA
25.01
EV/Sales
10.2
Revenue
$8.92B
EBIT
$3.13B
EBITDA
$3.63B
Free cash flow
$2.11B
Per share
Balance sheet
Liquidity
EPS
$5.11
Free cash flow per share
$4.62
Book value per share
$10.88
Revenue per share
$19.57
TBVPS
$22.39
Total assets
$14.17B
Total liabilities
$9.21B
Debt
$6.74B
Equity
$4.97B
Working capital
$4.41B
Debt to equity
1.36
Current ratio
3.45
Quick ratio
1.65
Net debt/EBITDA
1.42
Margins
Efficiency
Dividend
EBITDA margin
40.8%
Gross margin
70%
Net margin
26.3%
Operating margin
35.1%
Return on assets
16.5%
Return on equity
46.6%
Return on invested capital
23.6%
Return on capital employed
25.3%
Return on sales
35.1%
Dividend yield
0.88%
DPS
$1.67
Payout ratio
32.7%
ZTS stock price
How has the Zoetis stock price performed over time
Intraday
1.41%
1 week
3.13%
1 month
2.13%
1 year
1.27%
YTD
-4.12%
QTD
9.15%
Financial performance
How have Zoetis's revenue and profit performed over time
Revenue
$8.92B
Gross profit
$6.24B
Operating income
$3.13B
Net income
$2.34B
Gross margin
70%
Net margin
26.3%
ZTS's revenue is up by 8% YoY and by 2.1% QoQ
The gross profit has grown by 8% YoY
The operating margin has decreased by 6% YoY and by 4.9% from the previous quarter
The net income has grown by 6% YoY
Growth
What is Zoetis's growth rate over time
Valuation
What is Zoetis stock price valuation
P/E
37.03
P/B
17.39
P/S
9.67
EV/EBIT
29.03
EV/EBITDA
25.01
EV/Sales
10.2
The P/E is 8% lower than the 5-year quarterly average of 40.4 but 5% higher than the last 4 quarters average of 35.2
Zoetis's EPS has increased by 7% YoY
The stock's price to book (P/B) is 8% less than its 5-year quarterly average of 19.0 but 7% more than its last 4 quarters average of 16.3
ZTS's equity is up by 7% year-on-year
ZTS's revenue is up by 8% YoY and by 2.1% QoQ
ZTS's price to sales (P/S) is 7% lower than its 5-year quarterly average of 10.4
Efficiency
How efficient is Zoetis business performance
ZTS's ROIC is down by 6% YoY and by 3.7% QoQ
Zoetis's return on sales has decreased by 6% YoY and by 4.9% QoQ
ZTS's return on assets is up by 4.4% year-on-year but it is down by 2.4% since the previous quarter
The company's return on equity fell by 4.3% YoY and by 3.7% QoQ
Dividends
What is ZTS's dividend history
DPS
$1.67
Dividend yield
0.88%
Payout ratio
32.7%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Zoetis financials performed over time
ZTS's total assets is 54% greater than its total liabilities
Zoetis's quick ratio has decreased by 4.1% YoY and by 3.5% QoQ
The company's current ratio rose by 3.6% QoQ
The debt is 36% higher than the equity
ZTS's equity is up by 7% year-on-year
Zoetis's debt to equity has decreased by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.